{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T03:06:44Z","timestamp":1781406404654,"version":"3.54.1"},"reference-count":71,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"unspecified","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["204998\/Z\/16\/Z"],"award-info":[{"award-number":["204998\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,1,28]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Survival in men diagnosed with\n                      <jats:italic>de novo<\/jats:italic>\n                      synchronous metastatic prostate cancer has increased following the use of upfront systemic treatment, using chemotherapy and other novel androgen receptor targeted agents, in addition to standard androgen deprivation therapy (ADT). Local cytoreductive and metastasis-directed interventions are hypothesised to confer additional survival benefit. In this setting, IP2-ATLANTA will explore progression-free survival (PFS) outcomes with the addition of sequential multimodal local and metastasis-directed treatments compared with standard care alone.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A phase II, prospective, multicentre, three-arm randomised controlled trial incorporating an embedded feasibility pilot. All men with new histologically diagnosed, hormone-sensitive, metastatic prostate cancer, within 4\u2009months of commencing ADT and of performance status 0 to 2 are eligible. Patients will be randomised to Control (standard of care (SOC)) OR Intervention 1 (minimally invasive ablative therapy to prostate\u00b1pelvic lymph node dissection (PLND)) OR Intervention 2 (cytoreductive radical prostatectomy\u00b1PLND\u2009OR prostate radiotherapy\u00b1pelvic lymph node radiotherapy (PLNRT)). Metastatic burden will be prespecified using the Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease (CHAARTED) definition. Men with low burden disease in intervention arms are eligible for metastasis-directed therapy, in the form of stereotactic ablative body radiotherapy (SABR) or surgery. Standard systemic therapy will be administered in all arms with ADT\u00b1upfront systemic chemotherapy or androgen receptor agents. Patients will be followed-up for a minimum of 2\u2009years. Primary outcome: PFS. Secondary outcomes include predictive factors for PFS and overall survival; urinary, sexual and rectal side effects. Embedded feasibility sample size is 80, with 918 patients required in the main phase II component. Study recruitment commenced in April 2019, with planned follow-up completed by April 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Approved by the Health Research Authority (HRA) Research Ethics Committee Wales-5 (19\/WA0005). Study results will be submitted for publication in peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial pre-results\" xlink:href=\"NCT03763253\">NCT03763253<\/jats:ext-link>\n                      ; ISCRTN58401737\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-042953","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T11:59:38Z","timestamp":1614254378000},"page":"e042953","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03763253","registry":"10.18810\/clinical-trials-gov","type":"preResults"},{"clinical-trial-number":"nct01751438","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03655886","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"isrctn15704862","registry":"10.18810\/isrctn"},{"clinical-trial-number":"nct02716974","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03298087","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02489357","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02716974","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02716974","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01751438","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01751438","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03655886","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03655886","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02759783","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4033-7508","authenticated-orcid":false,"given":"Martin John","family":"Connor","sequence":"first","affiliation":[{"name":"Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK"},{"name":"Imperial Urology, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimur Tariq","family":"Shah","sequence":"additional","affiliation":[{"name":"Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Smigielska","sequence":"additional","affiliation":[{"name":"Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK"},{"name":"Imperial College Clinical Trials Unit, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Day","sequence":"additional","affiliation":[{"name":"Imperial College Clinical Trials Unit, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Sukumar","sequence":"additional","affiliation":[{"name":"Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK"},{"name":"Imperial College Clinical Trials Unit, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fiorentino","sequence":"additional","affiliation":[{"name":"Imperial College Clinical Trials Unit, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sarwar","sequence":"additional","affiliation":[{"name":"Department of Oncology, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Oncology, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Falconer","sequence":"additional","affiliation":[{"name":"Department of Oncology, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Klimowska-Nassar","sequence":"additional","affiliation":[{"name":"Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK"},{"name":"Imperial College Clinical Trials Unit, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Evans","sequence":"additional","affiliation":[{"name":"Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia Frances","family":"Naismith","sequence":"additional","affiliation":[{"name":"Radiotherapy Trials Quality Assurance (RTTQA), Royal Marsden NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7217-4593","authenticated-orcid":false,"given":"Kamalram","family":"Thippu Jayaprakash","sequence":"additional","affiliation":[{"name":"Department of Oncology, Addenbrooke\"s Hospital, Cambridge, Cambridgeshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Price","sequence":"additional","affiliation":[{"name":"Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Gayadeen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolan","family":"Basak","sequence":"additional","affiliation":[{"name":"Department of Oncology, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Horan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Addenbrooke\"s Hospital, Cambridge, Cambridgeshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McGrath","sequence":"additional","affiliation":[{"name":"Department of Urology, Royal Devon and Exeter NHS Foundation Trust, Exeter, Devon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Sheehan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Royal Devon and Exeter NHS Foundation Trust, Exeter, Devon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Urology, Arrowe Park Hospital, Wirral University Teaching Hospital NHS Foundation Trust, Wirral, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azman","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathryn","family":"Brock","sequence":"additional","affiliation":[{"name":"Department of Oncology, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Pearson","sequence":"additional","affiliation":[{"name":"Department of Oncology, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Anyamene","sequence":"additional","affiliation":[{"name":"Department of Oncology, London North West University Healthcare NHS Trust, Harrow, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Heath","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, University Hospital Southampton NHS Foundation Trust, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqbal","family":"Shergill","sequence":"additional","affiliation":[{"name":"Department of Urology, Wrexham Maelor Hospital, Wrexham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavan","family":"Rai","sequence":"additional","affiliation":[{"name":"Department of Urology, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giles","family":"Hellawell","sequence":"additional","affiliation":[{"name":"Department of Urology, Northwick Park Hospital, London North West University Healthcare NHS Trust, Harrow, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"McCracken","sequence":"additional","affiliation":[{"name":"Department of Urology, Sunderland Royal Hospital, Sunderland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijan","family":"Khoubehi","sequence":"additional","affiliation":[{"name":"Department of Urology, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Mangar","sequence":"additional","affiliation":[{"name":"Department of Oncology, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Khoo","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Royal Marsden NHS Foundation and Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Dudderidge","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Southampton NHS Foundation Trust, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7834-3172","authenticated-orcid":false,"given":"John Nicholas","family":"Staffurth","sequence":"additional","affiliation":[{"name":"Research, Velindre Cancer Centre, Cardiff, UK"},{"name":"Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Winkler","sequence":"additional","affiliation":[{"name":"Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK"},{"name":"Imperial Urology, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1674-6723","authenticated-orcid":false,"given":"Hashim Uddin","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK"},{"name":"Imperial Urology, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"2025121402495679000_11.2.e042953.1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.304"},{"key":"2025121402495679000_11.2.e042953.2","doi-asserted-by":"crossref","unstructured":"Connor MJ , Shah TT , Horan G . Cytoreductive treatment strategies for de novo metastatic prostate cancer. Nat Rev Clin Oncol doi:10.1038\/s41571-019-0284-3","DOI":"10.1038\/s41571-019-0284-3"},{"key":"2025121402495679000_11.2.e042953.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.09.032"},{"key":"2025121402495679000_11.2.e042953.4","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13253"},{"key":"2025121402495679000_11.2.e042953.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903307"},{"key":"2025121402495679000_11.2.e042953.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903835"},{"key":"2025121402495679000_11.2.e042953.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01037-5"},{"key":"2025121402495679000_11.2.e042953.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174"},{"key":"2025121402495679000_11.2.e042953.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"2025121402495679000_11.2.e042953.10","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.44"},{"key":"2025121402495679000_11.2.e042953.11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jamaoncol.2019.4724","article-title":"Survival in oligometastatic prostate cancer-a new dawn or the will Rogers phenomenon?","volume":"6","author":"Connor","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025121402495679000_11.2.e042953.12","doi-asserted-by":"crossref","DOI":"10.1038\/bjc.2013.192","article-title":"Circulating microRNAs as potential new biomarkers for prostate cancer","volume":"108","author":"Sita-Lumsden","year":"2013","journal-title":"Br J Cancer"},{"key":"2025121402495679000_11.2.e042953.13","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.369"},{"key":"2025121402495679000_11.2.e042953.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-5125"},{"key":"2025121402495679000_11.2.e042953.15","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.eururo.2016.05.023","article-title":"Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer","volume":"70","author":"Lorente","year":"2016","journal-title":"Eur Urol"},{"key":"2025121402495679000_11.2.e042953.16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ijc.28002","article-title":"Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients","volume":"133","author":"Lilleby","year":"2013","journal-title":"Int J Cancer"},{"key":"2025121402495679000_11.2.e042953.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1754"},{"key":"2025121402495679000_11.2.e042953.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0563"},{"key":"2025121402495679000_11.2.e042953.19","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.64"},{"key":"2025121402495679000_11.2.e042953.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.11.025"},{"key":"2025121402495679000_11.2.e042953.21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI43414"},{"key":"2025121402495679000_11.2.e042953.22","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-012-9373-9"},{"key":"2025121402495679000_11.2.e042953.23","doi-asserted-by":"publisher","DOI":"10.1038\/nature14347"},{"key":"2025121402495679000_11.2.e042953.24","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025121402495679000_11.2.e042953.25","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ijrobp.2018.06.105","article-title":"Stereotactic ablative radiation therapy for the comprehensive treatment of oligometastatic tumors (SABR-COMET): results of a randomized trial","volume":"102","author":"Palma","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025121402495679000_11.2.e042953.26","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0115"},{"key":"2025121402495679000_11.2.e042953.27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3109\/09553002.2014.874608","article-title":"Abscopal effect of radiation therapy: interplay between radiation dose and p53 status","volume":"90","author":"Strigari","year":"2014","journal-title":"Int J Radiat Biol"},{"key":"2025121402495679000_11.2.e042953.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112824"},{"key":"2025121402495679000_11.2.e042953.29","doi-asserted-by":"crossref","unstructured":"Brooks ED , Chang JY . Time to abandon single-site irradiation for inducing abscopal effects. Nat Rev Clin Oncol 2018;1.","DOI":"10.1038\/s41571-018-0119-7"},{"key":"2025121402495679000_11.2.e042953.30","first-page":"417","article-title":"Enhanced activated T cell subsets in prostate cancer patients receiving iodine-125 low-dose-rate prostate brachytherapy","volume":"39","author":"Kubo","year":"2018","journal-title":"Oncol Rep"},{"key":"2025121402495679000_11.2.e042953.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cryobiol.2008.10.126"},{"key":"2025121402495679000_11.2.e042953.32","doi-asserted-by":"publisher","DOI":"10.1016\/0011-2240(71)90050-2"},{"key":"2025121402495679000_11.2.e042953.33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41391-018-0035-z","article-title":"Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer","volume":"21","author":"Benzon","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2025121402495679000_11.2.e042953.34","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41391-019-0176-8","article-title":"A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer","volume":"23","author":"Ross","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2025121402495679000_11.2.e042953.35","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41391-020-0216-4","article-title":"Cytoreductive cryotherapy for newly diagnosed oligometastatic hormone-sensitive prostate cancer","volume":"23","author":"Connor","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2025121402495679000_11.2.e042953.36","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2016.175"},{"key":"2025121402495679000_11.2.e042953.37","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.crad.2019.05.003","article-title":"New concepts in prostate cancer management: the conundrum of managing oligometastatic disease in prostate cancer-through the looking glass darkly","volume":"74","author":"Khoo","year":"2019","journal-title":"Clin Radiol"},{"key":"2025121402495679000_11.2.e042953.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32486-3"},{"key":"2025121402495679000_11.2.e042953.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.008"},{"key":"2025121402495679000_11.2.e042953.40","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","article-title":"Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"key":"2025121402495679000_11.2.e042953.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64562-4"},{"key":"2025121402495679000_11.2.e042953.42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/bju.13992","article-title":"Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases?","volume":"121","author":"Jang","year":"2018","journal-title":"BJU Int"},{"key":"2025121402495679000_11.2.e042953.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.05.023"},{"key":"2025121402495679000_11.2.e042953.44","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1111\/bju.13925","article-title":"Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomized controlled feasibility trial","volume":"120","author":"Sooriakumaran","year":"2017","journal-title":"BJU Int"},{"key":"2025121402495679000_11.2.e042953.45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.euo.2018.03.002","article-title":"Cytoreductive radical prostatectomy in men with prostate cancer and skeletal metastases","volume":"1","author":"Heidenreich","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"2025121402495679000_11.2.e042953.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.012"},{"key":"2025121402495679000_11.2.e042953.47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.4788"},{"key":"2025121402495679000_11.2.e042953.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.09.089"},{"key":"2025121402495679000_11.2.e042953.49","unstructured":"ClinicalTrials.gov [Internet] . A study of definitive therapy to treat prostate cancer (oligo-mets).NCT02716974 . Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02716974 [Accessed 18 Feb 2021]."},{"key":"2025121402495679000_11.2.e042953.50","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-0195985-6"},{"key":"2025121402495679000_11.2.e042953.51","unstructured":"ClinicalTrials.gov [Internet] . Best systemic therapy (Bst) or Bst plus definitive treatment (radiation or surgery). NCT01751438 . Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01751438 [Accessed 18 Feb 2021]."},{"key":"2025121402495679000_11.2.e042953.52","unstructured":"ClinicalTrials.gov [Internet] . Cytoreductive prostatectomy versus cytoreductive prostate irradiation as a local treatment option for metastatic prostate cancer: a multicentric feasibility trial (LoMP II). NCT03655886 . Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03655886 [Accessed 18 Feb 2021]."},{"key":"2025121402495679000_11.2.e042953.53","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.kjms.2017.07.002","article-title":"Cytoreductive cryosurgery in patients with bone metastatic prostate cancer: a retrospective analysis","volume":"33","author":"Sheng","year":"2017","journal-title":"Kaohsiung J Med Sci"},{"key":"2025121402495679000_11.2.e042953.54","doi-asserted-by":"crossref","unstructured":"Shah TT , Peters M , Eldred-Evans D . Early-Medium-Term outcomes of primary focal cryotherapy to treat nonmetastatic clinically significant prostate cancer from a prospective multicentre registry. Eur Urol 2019.","DOI":"10.1016\/j.eururo.2018.12.030"},{"key":"2025121402495679000_11.2.e042953.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.06.004"},{"key":"2025121402495679000_11.2.e042953.56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4853"},{"key":"2025121402495679000_11.2.e042953.57","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.euo.2020.07.004","article-title":"Targeting oligometastasis with stereotactic ablative radiation therapy or surgery in metastatic hormone-sensitive prostate cancer: a systematic review of prospective clinical trials","volume":"3","author":"Connor","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"2025121402495679000_11.2.e042953.58","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.urology.2016.10.044","article-title":"A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer","volume":"102","author":"O\"Shaughnessy","year":"2017","journal-title":"Urology"},{"key":"2025121402495679000_11.2.e042953.59","unstructured":"NICE . Guideline updates team UK. prostate cancer: diagnosis and management, 2019."},{"key":"2025121402495679000_11.2.e042953.60","unstructured":"National Institute for Health and Care Excellence . Prostate cancer: diagnosis and management [B] Evidence review for docetaxel in people with hormone sensitive prostate cancer [NG131, 2019."},{"key":"2025121402495679000_11.2.e042953.61","unstructured":"Scottish Medicines Consortium . Abiraterone acetate with prednisone or prednisolone for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer in adult men in combination with androgen deprivation therapy [SMC2215, 2020."},{"key":"2025121402495679000_11.2.e042953.62","unstructured":"NHS England Clinical Commissioning . External beam radiotherapy for patients presenting with hormone sensitive, low volume metastatic prostate cancer at the time of diagnosis [P200802P] (URN: 1901, 2020."},{"key":"2025121402495679000_11.2.e042953.63","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0090-4295(03)00351-0","article-title":"Follow-Up of nondetectable prostate carcinoma (pT0) after prolonged PSA-monitored neoadjuvant hormonal therapy followed by radical prostatectomy","volume":"62","author":"K\u00f6llermann","year":"2003","journal-title":"Urology"},{"key":"2025121402495679000_11.2.e042953.64","doi-asserted-by":"crossref","DOI":"10.1159\/000343546","article-title":"pT0 prostate cancer: predictive clinicopathologic features in an American population","volume":"7","author":"Bream","year":"2013","journal-title":"Curr Urol"},{"key":"2025121402495679000_11.2.e042953.65","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1200\/JCO.18.01777","article-title":"Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone","volume":"37","author":"McKay","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025121402495679000_11.2.e042953.66","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/modpathol.2017.158","article-title":"Treatment effects in prostate cancer","volume":"31","author":"Evans","year":"2018","journal-title":"Modern Pathology"},{"key":"2025121402495679000_11.2.e042953.67","unstructured":"Syndikus I . ISRCTN80146950. A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (PIVOTALBoost, 2019."},{"key":"2025121402495679000_11.2.e042953.68","unstructured":"Khoo V . Conventional care versus Radioablation (stereotactic body radiotherapy) for extracranial Oligometastases (core) NCT02759783 , 2019."},{"key":"2025121402495679000_11.2.e042953.69","unstructured":"The Faculty of Clinical Oncology of The Royal College of Radiologists . Stereotactic ablative body radiation therapy (SABR): a resource. version 6.1, 2019."},{"key":"2025121402495679000_11.2.e042953.70","unstructured":"U.S. Department of health and human services . Common terminology criteria for adverse events (CTCAE) version 5.0, 2017."},{"key":"2025121402495679000_11.2.e042953.71","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS5600","article-title":"Initial experience of the adjuvant treatments to the local tumor for metastatic prostate cancer: assessment of novel treatment algorithms, a multicenter, phase II randomized controlled trial (IP2-ATLANTA)","volume":"38","author":"Connor","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-042953","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T10:50:07Z","timestamp":1765709407000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-042953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":71,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,25]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/bmjopen-2020-042953"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-042953","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}